Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.
Lagardere Shareholder Fight Appears Headed to Resolution publishersweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publishersweekly.com Daily Mail and Mail on Sunday newspapers.